相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- Phase III protocols now collect roughly 5.9 million data points on average, with data volume growing about 11% annually since 2020, making uniform oversight models progressively less effective. - ICH E6(R3) and FDA and MHRA guidance now call for quality-by-design, critical-to-quality factors and risk-proportionate monitoring instead of routine 100% source data verification. - An analysis of 18 oncology trials estimated trial-level returns on RBQM investment of six to 23 times, driven largely by 8% to 19% reductions in clinical-phase duration. - In 1,111 sites across 159 trials, 83% of sites flagged as at-risk by central statistical monitoring improved on predefined quality metrics after targeted investigation and follow-up.
- Manufacturing or quality deficiencies accounted for 74 percent of Complete Response Letters the US FDA issued between 2020 and 2024, underscoring that CMC issues—not clinical efficacy—drive most regulatory failures. - Three high-profile cell and gene therapy programs were delayed or rejected in a single month in summer 2025 for CMC-related reasons alone, reflecting systemic gaps in translating quality strategy into actionable timelines. - Regulatory frameworks, including ICH guidelines and the FDA's January 2026 flexible CMC guidance, expect critical quality attributes and product quality controls to be established early in development rather than at submission. - Early QC planning that accounts for limited material volume, short timelines, and cross-regional method transfer can protect cost and timeline while avoiding late-stage add-on testing and release delays.
- Multi-arm multi-stage (MAMS) platform trials offer a revolutionary approach to neurological drug development, addressing the 99.6% failure rate in Alzheimer's disease trials between 2002 and 2012. - The HEALEY ALS Platform Trial demonstrates successful implementation, evaluating four drugs through shared infrastructure in a fraction of the time required for sequential trials. - Regulatory gaps remain as the FDA lacks disease-specific guidance for CNS platform trials, despite acknowledging the opportunity for innovation in neurological drug development. - Neurological conditions represent the world's leading cause of ill health and disability, yet traditional sequential trial models remain incompatible with the pace of scientific discovery in this field.
- The European Medicines Agency has released draft guidance for conducting clinical trials during public health emergencies, marking the first EU guidance to reflect current legislative frameworks and lessons learned from COVID-19. - The guidance emphasizes prioritizing well-designed clinical trials over compassionate use programs to generate robust evidence for regulatory decision-making during emergencies. - New regulatory mechanisms are proposed to accelerate trial authorization and modifications during PHEs, with sponsors encouraged to seek advice from EMA's Emergency Task Force. - The draft guidance allows for protocol amendments, decentralized procedures, and patient transfers between sites to maintain trial continuity while ensuring patient safety during emergencies.
- The International Council for Harmonisation has opened public consultation on its draft Q3E guideline for extractables and leachables, which reached Step 2b of the ICH Process on August 1, 2025. - The framework expands existing ICH impurity guidelines to protect patient safety and product quality through assessment and control of leachable impurities in drug products. - The guideline follows ICH Q9 risk management principles and is expected to assist pharmaceutical companies in license applications for medicinal products, including cell and gene therapies. - The draft covers drug delivery device components and aims to help regulatory authorities assess products while focusing primarily on organic leachables.
- The International Council for Harmonisation (ICH) has released draft guideline E20 "Adaptive Designs for Clinical Trials" for public consultation, marking the first harmonized global framework for adaptive trial designs in drug development. - The guideline addresses four key principles for confirmatory trials including adequacy within development programs, proper trial planning, controlling erroneous conclusions, and maintaining reliable treatment effect estimates. - Stakeholders have until November 30, 2025 to provide comments on the draft, which aims to provide clarity on terminology, benefits, and implementation challenges of adaptive designs while maintaining regulatory evidence standards. - The draft follows five and a half years after the FDA's 2019 guidance on adaptive designs, representing a significant step toward global regulatory harmonization in innovative clinical trial methodologies.
- The European Medicines Agency has released new guidance recommending that pregnant and breastfeeding women should be included in clinical trials for all medicines intended for people who can potentially give birth to children. - Currently, less than 0.4% of EU clinical trials include pregnant participants and only 0.1% include lactating individuals, leading to treatment decisions made without essential safety and efficacy data. - The new guideline, developed through the International Council for Harmonisation, represents a "change in paradigm" and is open for public consultation until September 15th. - The guidance aims to address suboptimal treatment decisions and potential harm caused by lack of pregnancy-specific data in product leaflets.
- The European Medicines Agency (EMA) has adopted comprehensive new guidelines outlining specific requirements for clinical-stage Advanced Therapy Medicinal Products (ATMPs), enhancing regulatory clarity for developers. - The guidelines address critical aspects including manufacturing standards, preclinical studies, and clinical trial design considerations for cell and gene therapies. - Special emphasis is placed on pediatric applications and risk management strategies, aligning with ICH standards while adapting to the unique challenges of advanced therapies.
• Community-based research sites achieve over 50% minority participation in clinical trials, significantly exceeding the industry average of 20%, while maintaining a 92% retention rate. • Advanced mobile healthcare facilities and hospital-affiliated research centers enable complex trial execution while maintaining rigorous regulatory compliance and quality standards. • Strategic placement of research sites within communities reduces travel burden and enhances participant engagement, challenging traditional clinical trial models centered in urban academic institutions.
- The International Council for Harmonisation (ICH) has released draft E6(R3) guidelines aimed at modernizing Good Clinical Practice standards, with final implementation expected in 2025. - The new guidelines introduce a risk-proportionate approach to clinical trial management, replacing rigid Quality Tolerance Limits with more flexible 'Acceptable Ranges' to enhance trial efficiency. - E6(R3) addresses the challenges of managing increasing data volumes in clinical trials, with studies now handling up to 6 million data points and multiple data sources.
